The IMPACT-FH Renewal Protocol: Evaluating FH Cascade Testing Implementation in Primary Care through a Pragmatic Trial, Economic Evaluation, and Mixed-Methods Sustainability Assessment

Public Health Genomics. 2026 Jun 12:1-26. doi: 10.1159/000552982. Online ahead of print.ABSTRACTINTRODUCTION: Familial hypercholesterolemia (FH) is a common autosomal dominant genetic disorder conferring a high risk of premature atherosclerotic cardiovascular disease (ASCVD), without early diagnosis

K Kelly M Morgan

Causal associations between antibody-mediated immune responses to infectious agents and cardiovascular inflammatory diseases: A Mendelian randomization study based on UK Biobank and FinnGen

Hum Vaccin Immunother. 2026 Dec;22(1):2687297. doi: 10.1080/21645515.2026.2687297. Epub 2026 Jun 12.ABSTRACTA two-sample Mendelian randomization study was performed to evaluate causal associations between 46 pathogen-specific antibodies and six cardiovascular inflammatory diseases: myocarditis, peri

Q Qi Huang

The Take-Home Heart Monitoring Boom

IEEE Pulse. 2026 Mar-Apr;17(2):23-26. doi: 10.1109/MPULS.2026.3677910.ABSTRACTA new generation of noninvasive, FDA-cleared devices is making continuous heart monitoring more accessible to address cardiovascular disease. As healthcare shifts toward outcomes-based models, these technologies promise mo

K Kristina Grifantini

Atherosclerotic cardiovascular disease modifies ambulatory blood pressure response to mandibular advancement device vs. CPAP in obstructive sleep apnoea (ASCVD modifies BP response to OSA therapy)

Eur J Prev Cardiol. 2026 Jun 12:zwag297. doi: 10.1093/eurjpc/zwag297. Online ahead of print.ABSTRACTAIMS: To determine whether baseline atherosclerotic cardiovascular disease (ASCVD) modifies the blood pressure (BP) response to mandibular advancement device (MAD) vs. continuous positive airway press

Y Yi-Hui Ou

Cardiac-targeted delivery of advanced medical therapies for heart disease

Eur Heart J. 2026 Jun 12:ehag432. doi: 10.1093/eurheartj/ehag432. Online ahead of print.ABSTRACTCardiovascular diseases (CVD) are the leading causes of death and disability worldwide with their global burden on the rise due to the ageing population and escalating prevalence of CVD risk factors, such

X Xiao Liu

Albuminuria and heart failure

Eur Heart J. 2026 Jun 12:ehag426. doi: 10.1093/eurheartj/ehag426. Online ahead of print.ABSTRACTAlbuminuria, typically measured by urinary albumin-to-creatinine ratio, is present in nearly half of all patients with heart failure. Even at low levels, albuminuria is a well-established, independent ris

J Javed Butler

Artificial Intelligence in Biomedical Scientific Publishing

Eur Heart J. 2026 Jun 12:ehag494. doi: 10.1093/eurheartj/ehag494. Online ahead of print.ABSTRACTArtificial intelligence is now embedded across the scientific research and publishing ecosystem, influencing discovery, analysis, knowledge translation, authorship, peer review, and editorial workflows. I

T Tomasz J Guzik

Visual Impairment and Cardiovascular Risk Factors in Hispanic and Latino Adults

JAMA Netw Open. 2026 Jun 1;9(6):e2617975. doi: 10.1001/jamanetworkopen.2026.17975.ABSTRACTIMPORTANCE: Visual impairment (VI) affects approximately 7 million individuals in the US and is associated with adverse outcomes; cardiovascular disease (CVD) risk factors and nonmedical drivers of health (NMDO

C Charlotte E Joslin

National Institutes of Health-Supported Research on Ultraprocessed Foods

JAMA Netw Open. 2026 Jun 1;9(6):e2618248. doi: 10.1001/jamanetworkopen.2026.18248.ABSTRACTIMPORTANCE: Evidence continues to mount that ultraprocessed food (UPFs) may contribute to diet-related chronic diseases, including cardiovascular disease, obesity, diabetes, and some cancers. In the US, these c

B Bramaramba J Kowtha

Advances in Clinical Cardiology 2025: A Summary of Key Clinical Trials

Adv Ther. 2026 Jun 12. doi: 10.1007/s12325-026-03653-w. Online ahead of print.ABSTRACTINTRODUCTION: Over the course of 2025, numerous key clinical trials in the field of cardiology were published or presented at major international conferences. This review seeks to collate and summarise these trials

M Matthew Todd